Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 194

1.

Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.

Inwald EC, Ortmann O, Koller M, Zeman F, Hofstädter F, Evert M, Brockhoff G, Klinkhammer-Schalke M.

Breast Cancer Res Treat. 2017 May;163(1):119-130. doi: 10.1007/s10549-017-4151-6. Epub 2017 Feb 15.

PMID:
28205042
2.

Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.

Schüler-Toprak S, Häring J, Inwald EC, Moehle C, Ortmann O, Treeck O.

BMC Cancer. 2016 Dec 21;16(1):951. doi: 10.1186/s12885-016-2973-y.

3.

Current developments in cancer care: including the patients' perspective-3rd European Roundtable Meeting (ERTM) June 17, 2016, Berlin, Germany.

Ortmann O, Rösler W, Helbig U; participants of the ERTM..

J Cancer Res Clin Oncol. 2017 Apr;143(4):673-676. doi: 10.1007/s00432-016-2320-3. Epub 2016 Dec 17. Review.

PMID:
27988842
4.

IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).

Wege AK, Weber F, Kroemer A, Ortmann O, Nimmerjahn F, Brockhoff G.

Oncotarget. 2017 Jan 10;8(2):2731-2744. doi: 10.18632/oncotarget.13159.

5.

[Screening for cervical and breast cancer].

Wilm J, Schüler-Toprak S, Ortmann O.

Pathologe. 2016 Sep;37(5):477-89. doi: 10.1007/s00292-016-0228-y. German.

PMID:
27577734
6.

Message from the Editor-in-Chief.

Ortmann O.

Arch Gynecol Obstet. 2016 Sep;294(3):445. doi: 10.1007/s00404-016-4147-1. No abstract available.

PMID:
27405612
7.

Antenatal Diagnosis of Dizygotic, Monochorionic Twins Following IVF/ICSI.

Korsun P, Bals-Pratsch M, Ortmann O, Markus S, Germer U.

Geburtshilfe Frauenheilkd. 2016 Jun;76(6):727-730.

8.

Effects of morcellation on long-term outcomes in patients with uterine leiomyosarcoma.

Nemec W, Inwald EC, Buchholz S, Klinkhammer Schalke M, Gerken M, Ortmann O.

Arch Gynecol Obstet. 2016 Oct;294(4):825-31. doi: 10.1007/s00404-016-4086-x. Epub 2016 Apr 22.

PMID:
27105972
9.

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer.

Harter P, du Bois A, Mahner S, Pfisterer J, Ortmann O, Marth C, Fink D, Hilpert F, Wagner U, Sehouli J.

Geburtshilfe Frauenheilkd. 2016 Feb;76(2):147-149.

10.
11.

Molecular profiling of estrogen receptor α and progesterone receptor transcript variants in endometrial cancer.

Skrzypczak M, Merx I, Schüler-Toprak S, Weber F, Inwald EC, Ortmann O, Treeck O.

Steroids. 2015 Dec;104:122-8. doi: 10.1016/j.steroids.2015.09.004. Epub 2015 Sep 30.

PMID:
26428028
12.

4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival.

Inwald EC, Koller M, Klinkhammer-Schalke M, Zeman F, Hofstädter F, Gerstenhauer M, Brockhoff G, Ortmann O.

Breast Cancer Res Treat. 2015 Oct;153(3):647-58. doi: 10.1007/s10549-015-3572-3. Epub 2015 Sep 14.

13.

Message from the editor in chief.

Ortmann O.

Arch Gynecol Obstet. 2015 Oct;292(4):705-6. doi: 10.1007/s00404-015-3829-4. No abstract available.

PMID:
26296940
14.

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.

Inwald EC, Koller M, Klinkhammer-Schalke M, Zeman F, Hofstädter F, Lindberg P, Gerstenhauer M, Schüler S, Treeck O, Ortmann O.

J Cancer Res Clin Oncol. 2015 Dec;141(12):2229-40. doi: 10.1007/s00432-015-2025-z. Epub 2015 Aug 8.

15.

Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor®) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors.

Donders G, Bellen G, Neven P, Grob P, Prasauskas V, Buchholz S, Ortmann O.

Eur J Clin Microbiol Infect Dis. 2015 Oct;34(10):2023-8. doi: 10.1007/s10096-015-2447-1. Epub 2015 Jul 30.

16.

Invasive mole in a perimenopausal woman: a case report and systematic review.

von Welser SF, Grube M, Ortmann O.

Arch Gynecol Obstet. 2015 Dec;292(6):1193-9. doi: 10.1007/s00404-015-3777-z. Epub 2015 Jun 7. Review.

PMID:
26050078
17.

Improving cancer care in Europe: Which institutional health structures might be beneficial and why? 1. European Roundtable Meeting (ERTM), 16th May 2014, Berlin, Germany.

Ortmann O, Helbig U, Torode J; participants of the ERTM..

J Cancer Res Clin Oncol. 2016 Jan;142(1):1-4. doi: 10.1007/s00432-014-1906-x. Epub 2015 Feb 3.

PMID:
25644862
18.

Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators.; International Breast Cancer Study Group..

N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11.

19.

Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.

Buchholz S, Mögele M, Lintermans A, Bellen G, Prasauskas V, Ortmann O, Grob P, Neven P, Donders G.

Climacteric. 2015 Apr;18(2):252-9. doi: 10.3109/13697137.2014.991301. Epub 2015 Jan 20.

PMID:
25427450
20.

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.

Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, Segerer S, Kwok CW, Ortmann O, Engel JB.

BMC Cancer. 2014 Nov 19;14:847. doi: 10.1186/1471-2407-14-847.

Supplemental Content

Loading ...
Support Center